SCHEMBL5217205

SCHEMBL5217205

COC(=O)c1cnc(Cc2c(Cl)cccc2Cl)[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.56
▸ ABL1 P00519 4/20 0.53
▸ SRC P12931 4/20 0.53
▸ TAAR1 Q96RJ0 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ PDE3B Q13370 1/20 0.40
▸ PDE3A Q14432 1/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CDK5 Q00535 1/20 0.39
▸ CDK5R1 Q15078 1/20 0.39
▸ NR4A2 P43354 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14422199 0.83 TAAR1 (0.46) MMP2ABL1SRCTAAR1KMT2A
Hydrochloric Acid SCHEMBL5215090 0.82 TAAR1 (0.45) MMP2ABL1SRCTAAR1KMT2A
SCHEMBL14422201 0.75 KMT2A (0.45) MMP2SMN1; SMN2KMT2ANPSR1TDP1
SCHEMBL7424608 0.75 MMP2 (0.61) MMP2ABL1SRCCYP1A2POLB
SCHEMBL14422198 0.73 TRPV1 (0.48) —
SCHEMBL20630811 0.73 MMP2 (0.60) MMP2ABL1SRCCYP1A2ALDH1A1
SCHEMBL4605593 0.73 MMP2 (0.60) MMP2ABL1SRCCYP1A2POLB
SCHEMBL28296065 0.73 MMP2 (0.56) MMP2ABL1SRCCYP1A2ALDH1A1
SCHEMBL9939614 0.72 MMP2 (1.00) MMP2KMT2AMEN1
SCHEMBL31373939 0.72 MMP2 (0.58) MMP2ABL1SRCCYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 — — US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 — — US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 — — US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 — — EP disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 — — EP disclosed
EP-1603905-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-12-14 — — EP disclosed
WO-2004072068-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-08-26 — — WO disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 MMP2 1292/4885ABL1 1502/4885SRC 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback